Shire Sells Dermagraft To Organogenesis At $650M Loss

Law360, New York (January 17, 2014, 12:30 PM EST) -- Irish biopharmaceuticals company Shire PLC announced Friday that it has sold its skin substitute product Dermagraft to U.S.-based Organogenesis Inc. in a deal that pays Shire nothing upfront and leaves it with a $650 million loss.

Under the deal, Shire instead will be entitled to receive up to $300 million cash in total milestone payments should Organogenesis, a regenerative medicine company based in Canton, Mass., meet certain annual net sales targets for Dermagraft between now and 2018, Shire said in a statement.

The Dermagraft assets, valued...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.